skip to main |
skip to sidebar
It is an agreement of “Mutual collaboration and assistance”. LIF will do health controls and monitoring to its employees. Santa Fe’s Health Ministry participated in the signature.
Andrea Uboldi (Santa Fe’s Health Ministry); Fabián Mendoza (Sayago Hospital’s Director); Jorge Stettler and Diego Bruno (LIF’s Directors) signed an agreement of “Mutual collaboration and assistance”.
The main objective will be to do health controls and monitoring on the LIF’s staff members. Production Area’s staff will be the first group of employees to start the controls.
“LIF and Sayago Hospital are neighbours and have had a long history of activities together. Doing these controls by the Public Health Service strengthens both institutions”, expressed Jorge Stettler.
“This is an innovative idea. We want to monitor the health of our workers and prevent possible diseases”, said Andrea Uboldi.
“Through the medical histories we can monitor the health of the workers and take preventive measures to avoid diseases in the future”, said Fabián Mendoza.
Some Health Ministries from different provinces and authorities of COSSPRA* visited LIF. They met with LIF’s Directors and explored the facilities.
Some Health Ministries, Presidents and referents of public health insurances from different provinces such as: Tierra del Fuego, Chubut, Río Negro, Misiones, Entre Ríos, San Juan, Jujuy, Tucumán and Catamarca participated in this activity.
First, Andrea Uboldi (Santa Fe’s Health Ministry) welcomed the visitors.
Second, they met with LIF’s Board of Directors where they received information about public production of medicines and the different projects in progress.
After that, the group explored the different facilities with a guided tour.
Finally, the visitors, LIF’s Directors and staff members shared a lunch and exchanged their experiences.
*COSSPRA is the Provincial Federation of Social Health Insurance of Argentina.
It will be through an agreement with the Pharmacy School (UNR*) and LAFEDAR S.A. (from Entre Ríos province). It will require $ 5 million (ARG) as initial investment.
The main objective is to develop and produce five new medicines, such as: Atorvastatin 20 mg, Clarithromycin 500 mg, Losartan 50 mg, Metformin 850 mg (all of them in tablets) and Pediatric Ibuprofen 2% in syrup. At the beginning, these medicines will be delivered in the healthcare system of Santa Fe province.
Biochemistry and Pharmacy School of UNR, LAFEDAR S.A. and LIF will work to develop these medicines through this agreement. As a result of this, in fifteen months LIF will have the know how to produce them in its facilities.
Andrea Uboldi (Santa Fe’s Health Ministry), Jorge Stettler, Carlos Arques, Diego Bruno and Guillermo Cleti (LIF’s Boards of Directors) and Ricardo Guimarey (LAFEDAR S.A. Chief) signed the agreement.
“We celebrated this agreement between public and private institutions through which LIF will obtain the know how and technology to produce five new medicines. Due to this, more people will have a better access to chronic treatments in the healthcare system”, expressed Andrea Uboldi.
“Today, Santa Fe province is buying these five drugs. Through this agreement, LIF will be in perfect conditions to produce the medicines at LIF’s facilities from January 2020. A year and a half after that time, we hope to recover the initial investment of the project”, expressed Guillermo Cleti.
Horacio Coutaz (LIF’s Trustee) and Roberto Ganin (LIF’s General Manager) also participated in the meeting.
About the use of these drugs:
- Atorvastatin oral tablet is used to improve cholesterol levels and decrease your risk for heart attack and stroke.
- Losartan is used to treat high blood pressure (hypertension).
- Metformin is used to control high blood sugar. It is used in patients with type 2 diabetes.
- Clarithromycin is used to treat certain bacterial infections, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the ears, sinuses, skin, and throat.
- Pediatric Ibuprofen: it is analgesic and antipyretic.
*UNR: Universidad Nacional de Rosario.
